SCHEMBL4000418

SCHEMBL4000418

O=S(=O)(O)c1ccc(-c2ncc(-c3ccc(-c4cnc(-c5ccc(S(=O)(=O)O)cc5)o4)cc3)o2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
CASP1 P29466 1/20 0.58
RAB9A P51151 7/20 0.51
NPC1 O15118 6/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 4/20 0.51
HSD17B10 Q99714 4/20 0.51
GAA P10253 4/20 0.51
TP53 P04637 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
GLA P06280 1/20 0.51
CYP2C9 P11712 1/20 0.51
NFKB1 P19838 1/20 0.51
CYP2C19 P33261 1/20 0.51
CASP3 P42574 1/20 0.51
NFKB2 Q00653 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4000411 1.00 ALOX15 (0.58) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL6014725 0.89 CA1 (0.50) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL20356911 0.87 CA1 (0.49) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL10137864 0.85 MMP2 (0.43) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL9333789 0.81 CA12 (0.46) ALOX15TSHRCASP1NPC1KDM4E
SCHEMBL12336359 0.80 PTPN1 (0.46) RAB9ANPC1GAATP53LMNA
SCHEMBL1179970 0.76 HSD17B1 (0.72) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL6014360 0.74 CA1 (0.51) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL4650170 0.74 ALOX15 (0.41) ALOX15TSHRCASP1RAB9ANPC1
SCHEMBL12231198 0.74 CA1 (0.51) ALOX15TSHRCASP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10894037-B2 Inhibitors of bacterial two component signal transduction system and uses thereof ACADEMIA SINICA (TW) 2021-01-19 US disclosed
US-20190192487-A1 INHIBITORS OF BACTERIAL TWO COMPONENT SIGNAL TRANSDUCTION SYSTEM AND USES THEREOF ACADEMIA SINICA (TW) 2019-06-27 US disclosed
EP-1344055-A4 MATERIALS FOR ENHANCING STAINING OF BIOPOLYMERS IN MATRICES INVITROGEN CORP (US) 2009-03-25 EP disclosed
US-7144738-B2 Materials for enhancing staining of biopolymers in matrices WHITNEY SCOTT 2006-12-05 US disclosed
US-20050170517-A1 Materials for enhancing staining of biopolymers in matrices INVITROGEN CORPORATION (US) 2005-08-04 US disclosed
US-6878551-B2 For proteins/polypeptides within polyacrylamide matrix; mass spectrometry INVITROGEN CORPORATION (US) 2005-04-12 US disclosed
US-20040038418-A1 Materials for enhancing staining of biopolymers in matrices INVITROGEN CORPORATION 2004-02-26 US disclosed
US-6635489-B2 Sensitizing the matrix with heteroaromatic compounds, contacting with reduceable metal salts to stain and detecting INVITROGEN CORPORATION 2003-10-21 US disclosed
EP-1344055-A1 MATERIALS FOR ENHANCING STAINING OF BIOPOLYMERS IN MATRICES INVITROGEN CORPORATION (US) 2003-09-17 EP disclosed
US-20020137222-A1 Materials for enhancing staining of biopolymers in matrices INVITROGEN CORPORATION 2002-09-26 US disclosed
WO-2002042764-A1 MATERIALS FOR ENHANCING STAINING OF BIOPOLYMERS IN MATRICES INVITROGEN CORPORATION (US) 2002-05-30 WO disclosed
EP-0175371-B1 METHOD FOR SILVER STAINING PROTEINS AND NUCLEIC ACIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-03-14 EP disclosed
US-4710319-A Autofluorogram composition E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-01 US disclosed
EP-0175371-A2 Method for silver staining proteins and nucleic acids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1986-03-26 EP disclosed
US-4575452-A Kit for silver staining proteins and nucleic acids E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10894037-B2 Inhibitors of bacterial two component signal transduction system and uses thereof PGLS, BLVRB, COASY ALOX15 2434/4885TSHR 1763/4885CASP1 3835/4885
US-20190192487-A1 INHIBITORS OF BACTERIAL TWO COMPONENT SIGNAL TRANSDUCTION SYSTEM AND USES THEREOF PGLS, BLVRB, COASY ALOX15 2434/4885TSHR 1763/4885CASP1 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.